[{"from": "human", "value": "Provide a brief overview of this molecule. [H+1].[H+1].[C][C][N][Branch2][=Branch1][Ring2][C][C][N][Branch2][Branch1][Branch2][C@@H1][Branch2][Ring1][=Branch1][C][N][Branch1][N][C][C][N][Ring1][N][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1][C][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=S][N][C][C][C][C][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O-1][N][C][C][=Branch1][C][=O][O-1][C][C][=Branch1][C][=O][O-1].[177Lu+3]"}, {"from": "gpt", "value": "The molecule is a radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas."}]